Drug intelligence / Profile preview

BRT-FC-83C

Development stage: Discontinued
Lead developer: Biomed Research Technologies
Modality: Small Molecules
Administration: Topical

Overview

**BRT-FC-83C** is a topical small molecule drug developed for the treatment of mild to moderate atopic dermatitis, a chronic inflammatory skin condition[1][4]. Its highest development phase was Phase 2 in clinical trials targeting atopic dermatitis, but the drug has since been discontinued[1]. The mechanism of action, specific target, and molecular details are not disclosed or publicly available from current sources[1]. The drug was originated and sponsored by Biomed Research Technologies, Inc.[1][4].

Brand names: BRT-FC-83CBRT-FC83CBRT-FC 83C
Other names: BRT-FC-83CBRT-FC83CBRT-FC 83C

Beyond the preview

Go deeper on BRT-FC-83C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRT-FC-83C.

Explore the full profile